Literature DB >> 19567244

Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria.

Ingrid Zechmeister1, Birgitte Freiesleben de Blasio, Geoff Garnett, Aileen Rae Neilson, Uwe Siebert.   

Abstract

OBJECTIVE: The study predicts long-term cervical cancer related population health and economic effects of introducing the HPV-vaccination for 12-year-old girls (and boys) in addition to current screening compared with screening only.
METHOD: Health effects are predicted by a dynamic transmission model. Model results are used to calculate incremental cost-effectiveness ratios (ICER) in euro per life year gained (LYG) for a time-horizon between 2008 and 2060 from a public payer and a societal perspective.
RESULTS: Vaccination of girls results a discounted ICER of euro 64,000/LYG and euro 50,000/LYG from a payer's and societal perspectives respectively. The additional vaccination of boys increases the ICER to euro 311,000 and euro 299,000/LYG respectively. Results were most sensitive to vaccination price, discount rate and time-horizon.
CONCLUSION: HPV-vaccination for girls should be cost-effective when adopting a longer time-horizon and a societal perspective. Applying a shorter time frame and a payer's perspective or vaccinating boys may not be cost-effective without reducing the vaccine price.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19567244     DOI: 10.1016/j.vaccine.2009.06.039

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

Review 1.  A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus.

Authors:  Yiling Jiang; Aline Gauthier; Maarten J Postma; Laureen Ribassin-Majed; Nathalie Largeron; Xavier Bresse
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

Review 2.  Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses.

Authors:  Mireia Diaz; Silvia de Sanjosé; F Xavier Bosch; Laia Bruni
Journal:  Rep Pract Oncol Radiother       Date:  2018-04-26

3.  [Opinion on Schwarz E., Maier M. Publication output in the field of Public Health and its appreciation at political level in Austria, Wien Med Wochenschr (2014) 164:123-130].

Authors:  Brigitte Piso; Ingrid Zechmeister-Koss; Claudia Wild
Journal:  Wien Med Wochenschr       Date:  2014-12

Review 4.  Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.

Authors:  Mohamed-Béchir Ben Hadj Yahia; Anaïs Jouin-Bortolotti; Benoît Dervaux
Journal:  Clin Drug Investig       Date:  2015-08       Impact factor: 2.859

Review 5.  Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness.

Authors:  Nyi Nyi Soe; Jason J Ong; Xiaomeng Ma; Christopher K Fairley; Phyu Mon Latt; Jun Jing; Feng Cheng; Lei Zhang
Journal:  Hum Vaccin Immunother       Date:  2018-09-11       Impact factor: 3.452

Review 6.  Economic evaluation of human papilloma virus vaccination in the European Union: a critical review.

Authors:  Daniela Koleva; Paola De Compadri; Anna Padula; Livio Garattini
Journal:  Intern Emerg Med       Date:  2011-02-11       Impact factor: 3.397

Review 7.  Modeling preventative strategies against human papillomavirus-related disease in developed countries.

Authors:  Karen Canfell; Harrell Chesson; Shalini L Kulasingam; Johannes Berkhof; Mireia Diaz; Jane J Kim
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

Review 8.  The cost effectiveness of human papillomavirus vaccines: a systematic review.

Authors:  Katherine Seto; Fawziah Marra; Adam Raymakers; Carlo A Marra
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

9.  Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females.

Authors:  Diane M Harper; Stephen L Vierthaler
Journal:  ISRN Obstet Gynecol       Date:  2011-11-02

Review 10.  Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2014-07       Impact factor: 11.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.